Details for Patent: 5,824,658

Title:	Topical composition containing hyaluronic acid and NSAIDS
Abstract:	A method of treating pain topically, said method comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage amount comprising (1) a non-steroidal anti-inflammatory drug (NSAID) in a therapeutically effective amount to treat pain of the skin or exposed tissue and (2) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, its non-toxic salts and combination thereof being between 1% and 3% by weight of the composition, characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin or exposed tissue and in a dosage amount in which component (2) exceeds 10 mg/cm.sup.2 of the skin or exposed tissue to which the dosage amount is to be applied, and is in such form that component (2) is immediately available to transport component (1) percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of pain to be treated, in the skin or exposed tissue, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons.
Inventor(s):	Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel Simon (Toronto, CA)
Assignee:	Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:	Aug 07, 1995
Application Number:	08/468,329
Claims:	1. A method of treating pain topically, said method comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage amount comprising: (1) a non-steroidal anti-inflammatory drug (NSAID) in a therapeutically effective amount to treat pain of the skin or exposed tissue and; (2) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, its non-toxic salts and combination thereof being between 1% and 3% by weight of the composition, characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin or exposed tissue and in a dosage amount in which component (2) exceeds 10 mg/cm.sup.2 of the skin or exposed tissue to which the dosage amount is to be applied, and is in such form that component (2) is immediately available to transport component (1) percutaneously into the epidermis of the skin or exposed tissue to the site of trauma pathology of pain to be treated, in the skin or exposed tissue, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons. 2. The method of claim 1 wherein component (2) is sodium hyaluronate being between 1% to 3% by weight of the composition. 3. The method of claim 1 or 2 wherein component (1) is between 1% to 5% by weight of the composition. 4. The method of claim 1 or 2 wherein the NSAID is diclofenac sodium. 5. The method of claim 2 wherein component (2) is sodium hyaluronate whose molecular weight is between 150,000 daltons and 225,000 daltons. 6. The method of claim 1 or 2 wherein the NSAID is selected from the group consisting of diclofenac, didofenac sodium, ibuprofen, piroxicam, flunixen and flunixen meglurmine. 7. The method of claim 1 or 2 wherein the pharmaceutical composition further comprises suitable topical excipients. 8. The method of claim 1 or 2 wherein the administering takes place a number of times a day over a number of weeks. 9. A method of treating pain topically, said method comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage amount comprising: (1) a non-steroidal anti-inflammatory drug (NSAID) in a therapeutically effective amount to treat pain of the skin or exposed tissue and; (2) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, its non-toxic salts and combination thereof, characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin or exposed tissue and in a dosage amount in which component (2) exceeds 10 mg/cm.sup.2 of the skin or exposed tissue to which the dosage amount is to be applied, and is in such form that component (2) is immediately available to transport component (1) percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of pain to be treated, in the skin or exposed tissue, and wherein component (1) is between 1% and 5% by weight of the composition and component (2) is between 1% and 3% by weight of the composition and has a molecular weight of less than 750,000 daltons and greater than 150,000 daltons. 10. The method of claim 9 wherein component (2) is sodium hyaluronate and component (1) is selected from the group consisting of diclofenac, diclofenac sodium, ibuprofen, piroxicam, flunixen and flunixen meglumine.